Takeda's top-selling drug is Entyvio (vedolizumab).
Entyvio is a targeted biologic therapy primarily prescribed for the treatment of moderate to severe active ulcerative colitis and Crohn's disease, both chronic inflammatory bowel conditions. It works by specifically targeting inflammation in the gut, offering a crucial treatment option for patients who have not responded adequately to conventional therapies. Its consistent performance makes it a cornerstone of Takeda's pharmaceutical portfolio.
Takeda's drug lineup features several high-performing assets that contribute significantly to its global market presence. While various drugs contribute to the company's revenue, Entyvio has maintained its position as the leading product by sales volume.
Here's an overview of the growth performance of some of Takeda's key drugs:
| Drug | Indication | Growth (+/-%) |
|---|---|---|
| Entyvio | Ulcerative colitis, Crohn's disease | 22% |
| Immunoglobulin | Immunoglobulin deficiency | 15% |
| Takhzyro | Hereditary angioedema | 19% |
| Albumin | PDT | 56% |
As shown, while drugs like Albumin have demonstrated exceptional percentage growth, Entyvio consistently leads in overall sales, reaffirming its status as Takeda's top pharmaceutical product. Other significant contributors, such as Takhzyro and Immunoglobulin, also play vital roles in bolstering the company's robust pipeline and financial strength.
